小智港股覆盤 | 3月7日
今日，港股三大指數集體下跌。截止收盤，恆生指數大跌3.87%，報21057點。國企指數大跌3.57%，報7412點。恆生科技指數大跌4.43%，報4527點。市場約324只個股上漲，1525只個股下跌。成交額突破1775.95億港幣，和昨天同期相比增長7.78%。南下資金淨流入54.49億港幣。
盤面上，有色金屬和鋼鐵板塊集體拉昇。俄鋁漲超34%；新疆新鑫礦業、招金礦業等多股漲超13%；中國黃金國際漲超12%；中國大冶有色金屬漲超8%。俄鋁尾盤飆升逾30%，傳En+正在探索拆分俄羅斯鋁業國際業務，倫鋁創記錄新高；深港通下港股通股票名單調整：調入中國黃金國際等個股，調出恆隆集團等。
電力板塊活躍。電能實業漲超3%；長江基建集團漲超2%。長江基建電能確認英國電力資產獲洽購。
能源設備板塊活躍。惠生工程漲超13%；勝利管道漲超4%；華油能源漲超3%；海隆控股漲超2%；中海油田服務漲超1%。勝利渠道預期全年淨虧損不超過2.65億元，同比減少約18.5%；華油能源預期年度淨利潤不超過1000萬元，扭虧爲盈。
航空板塊全線走低。中國國航跌超9%；國泰航空、中國南方航空股份等多股跌超8%；中國東方航空股份跌超5%。中金髮布中資股策略首選名單：安踏體育、中國國航上榜；大摩上調國泰目標價至8.2元，評級「增持」；中國東方航空股份：3月14日開始支付2021年公司債券(第一期)品種一的利息。
CRO板塊暴跌。藥明生物跌超9%；奧星生命科技、中國醫療集團等多股跌超8%；泰格醫藥、金斯瑞生物科技等多股跌超5%。奧星生命科技午後升超5%，完成收購南京博健科技的方的產品技術；NINETY ONE UK LIMITED增持泰格醫藥32.08萬股，每股作價約90.89港元；金斯瑞生物科技(1548.HK)高開6.97% FDA批準CARVYKTITM用於治療復發或難治性多發性骨髓瘤成人患者。
個人用品板塊全線走低。中智藥業跌超14%；L'OCCITANE跌超10%；中生聯合、恆安國際等多股跌超4%；金嗓子跌超2%。L‘OCCITANE自庫存轉撥7.36萬股普通股；中生聯合預期2021年虧損收窄38%至3100萬元；恆安國際合共完成發行20億元短期融資券。
uSMART智能寫手的信息、數據均來自媒體公開報道，智能寫手不能保證其完全準確，內容僅供參考，不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
